Gland Pharma bags USFDA nod for breast cancer treatment injection Eribulin Mesylate
"The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner," Gland Pharma stated.
Hyderabad: Gland Pharma Limited, a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).
Eribulin Mesylate Injection is used for the treatment of breast cancer that has spread to other parts of the body.
"The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner," Gland Pharma stated.
The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA.
The Company is co-developing several complex injectables, including this Product, with Orbicular Pharmaceutical Technologies Private Limited.
Read also: Gland Pharma bags tentative USFDA nod for Angiotensin II Injection for low BP treatment
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.